This prospective, single-site, pharmacokinetic, cohort study will examine the effects of obesity on plasma drug concentrations of efavirenz. Concentrations from two different times (random and 12-hour sample) will help form subject-specific pharmacokinetic drug curves to evaluate obesity's effects on efavirenz concentrations. Forty subjects (10 normal weight, 10 overweight, 10 obese, and 10 extremely obese) will be enrolled.
This pilot study is designed as a preliminary study to determine if a significant difference exists in the stool bacterial diversity of hospitalized patients on broad-spectrum antibiotics during different points in their course of therapy. Fecal samples will be collected from study subjects at pre-defined time intervals (baseline, >48 to 96 to 144 to <192 hours) during their course of antibiotic therapy. Stool samples will be analyzed for the number and abundance (diversity) of bacterial species present.